<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Levobupivacaine: International drug information (concise)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Levobupivacaine: International drug information (concise)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Levobupivacaine: International drug information (concise)</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list fbnlist drugH1Div drugBrandNames" id="F25233301"><span class="drugH1">International Brand Names</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine | Levobupivacaine Fresenius Kabi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Levobupivacaina g.e.s | Levobupivacaina normon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine | Levobupivacaine altan | Levobupivacaine kabi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Levobupivacain</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine | Levobupivacain</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine | Levobupivacaina altan | Levobupivacaina bioindustria</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Popscaine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine | Levobupivacaine Fresenius Kabi</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Chirocaine</span></li></ul></div>
</div>
</div>
</div>
<div class="list synlist drugH1Div drugBrandNames" id="F25048727"><span class="drugH1">Index Terms</span>
<ul>
<li>(-)-bupivacaine;</li>
<li>(S)-bupivacaine;</li>
<li>L(-)-Bupivacaine;</li>
<li>Levobupivacaine Hydrochloride</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F25048561"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
<span class="list-set-name">Local Anesthetic</span></li></ul></div>
<div class="block iuse drugH1Div" id="F25048563"><span class="drugH1">Reported Use</span>
<p style="text-indent:0em;display:inline">Epidural pain management; surgical anesthesia</p></div>
<div class="block idos drugH1Div" id="F25048565"><span class="drugH1">Dosage Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose ranges are not intended to guide prescribing; consult local prescribing information for additional dosage and administration information.</p>
<p style="text-indent:-2em;margin-left:2em;">Children &gt;6 months to &lt;12 years: Surgical anesthesia: Local infiltration (Ilioinguinal/iliohypogastric block): 0.5 <b>mL</b>/kg/side of 0.25% solution (maximum: 1.25 <b>mg</b>/kg/side) or 0.25 <b>mL</b>/kg/side of 0.5% solution (maximum: 1.25 <b>mg</b>/kg/side).</p>
<p style="text-indent:-2em;margin-left:2em;">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">Surgical anesthesia:</p>
<p style="text-indent:-2em;margin-left:6em;">Dental: 5 to 10 <b>mL</b> of 0.5% to 0.75% solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Epidural:</p>
<p style="text-indent:-2em;margin-left:8em;">Cesarean section: 15 to 30 <b>mL</b> of 0.5% solution; maximum single dose: 150 <b>mg.</b></p>
<p style="text-indent:-2em;margin-left:8em;">Surgery, <b>not</b> cesarean section: 10 to 20 <b>mL</b> of 0.5% to 0.75% solution; maximum single dose: 150 <b>mg</b>; prolonged surgeries may require a maximum cumulative dose of 400 <b>mg</b>/24 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Intrathecal: 3 <b>mL</b> of 0.5% solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Local infiltration: 1 to 60 <b>mL</b> of 0.25% solution; maximum: 150 <b>mg.</b></p>
<p style="text-indent:-2em;margin-left:6em;">Ophthalmic (peribulbar block): 5 to 15 <b>mL</b> of 0.75% solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Peripheral nerve: 1 to 40 <b>mL</b> of 0.25% solution or 1 to 30 <b>mL</b> of 0.5% solution; maximum: 150 <b>mg.</b></p>
<p style="text-indent:-2em;margin-left:4em;">Pain management:</p>
<p style="text-indent:-2em;margin-left:6em;">Labor pain (epidural bolus): 6 to 20 <b>mL</b> of 0.25% solution.</p>
<p style="text-indent:-2em;margin-left:6em;">Labor pain (epidural infusion): 10 to 15 <b>mL</b>/hour of 0.0625% solution or 4 to 10 <b>mL</b>/hour of 0.125% solution (maximum: 12.5 <b>mg</b>/hour; a maximum cumulative dose of 400 <b>mg</b> per 24 hours is recommended).</p>
<p style="text-indent:-2em;margin-left:6em;">Peri- and postoperative pain (epidural infusion): 10 to 15 <b>mL</b>/hour of 0.0625% solution, or 10 to 15 <b>mL</b>/hour of 0.125% solution, or 5 to 7.5 <b>mL</b>/hour of 0.25% solution (maximum rate: 18.75 <b>mg</b>/hour; maximum cumulative dose: 400 <b>mg</b>/24 hours; however, postoperative doses up to 570 <b>mg</b>/24 hours have been well tolerated).</p></div>
<div class="block prod-avail drugH1Div" id="F25048564"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Product available in various countries; not currently available in the US</p></div>
<div class="block foc drugH1Div" id="F25048566"><span class="drugH1">Dosage Forms</span>
<p style="text-indent:-2em;margin-left:2em;">Solution, Infusion/Injection: 2.5 mg/mL, 5 mg/mL, 7.5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Infusion [premixed]: 0.625 mg/mL, 1.25 mg/mL (100 mL, 200 mL)</p></div>
</div><div id="topicVersionRevision">Topic 96003 Version 28.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
